Letter to the Editor
My colleagues and I recently noted that the article on correcting iron deficiency did not include up-to-date information on intravenous iron replacement therapy in Australian hospitals.1
Iron polymaltose has been used for decades and in the last five years there have been additional clinical studies across several Victorian hospitals looking into the safety and rapid administration of high doses.2-6 This information was omitted from the article despite the new data on safety and adaptation of the rapid infusion protocol for iron replacement using the safe and cheaper alternative to the newer product ferric carboxymaltose.
Many tertiary centres provide medication administration infusion services, which include iron polymaltose for management of iron deficiency anaemia. Using iron polymaltose negates the inconvenience of using ferric carboxymaltose on numerous occasions for doses over 1000 mg. This is common as the average dose for iron replacement is approximately 1200–1300 mg.
Patients who would benefit from ferric carboxymaltose are those with renal or heart failure who do not require doses over 1000 mg, and patients with mild–moderate iron deficiency requiring doses of 1000 mg or less with poor oral drug adherence or intolerance to oral supplements. These people can be treated with a single dose of ferric carboxymaltose.
Omission of this information for your readers does not provide them with a comprehensive update on current practice in the management of iron deficiency anaemia.
Peninsula Health, Vic.
Iouri Banakh has previously received a grant provided by the Society of Hospital Pharmacists of Australia and sponsored by Sanofi.
- Baird-Gunning J, Bromley J. Correcting iron deficiency. Aust Prescr 2016;39:193-9.
- Garg M, Morrison G, Friedman A, Lau A, Lau D, Gibson PR. A rapid infusion protocol is safe for total dose iron polymaltose: time for change. Intern Med J 2011;41:548-54.
- Tampi R, Herrmann R, Barr A, Wright M. Rapid iron infusion with iron polymaltose: further improvements may be possible. Intern Med J 2012;42:111.
- Banakh I, Lam A, Turek M, Htet TD, Vorlander C. Rapid versus standard iron polymaltose infusions: a single centre safety study. J Pharm Pract Res 2016 Nov 16 [Epub ahead of print].
- Chan PT, Corallo CE, Dooley MJ, Poole SG, Gibson PR. Safety of rapid infusion of iron polymaltose: comparative study in 300 patients. J Pharm Pract Res 2016;46:324-30.
- Newnham E, Ahmad I, Thornton A, Gibson PR. Safety of iron polymaltose given as a total dose iron infusion. Intern Med J 2006;36:672-4.
The Editorial Executive Committee welcomes letters, which should be less than 250 words. Before a decision to publish is made, letters which refer to a published article may be sent to the author for a response. Any letter may be sent to an expert for comment. When letters are published, they are usually accompanied in the same issue by their responses or comments. The Committee screens out discourteous, inaccurate or libellous statements. The letters are sub-edited before publication. Authors are required to declare any conflicts of interest. The Committee's decision on publication is final.